Price
$28.15+9.28%Social Signal Score
Analyst Ratings
20 analystsRevenue
$730.50M+8.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul A. Keel
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 12,000
- Beta
- 0.86
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.73
Financials
Revenue
$730.50M+8.6%Net Income
$53.70M+46.7%EBITDA
$83.10M+1.8%Free Cash Flow
$88.50M+494.0%EPS (diluted)
$0.33-34.0%Shares Outstanding (diluted)
164.10M+6.1%Operating Expenses
$326.70MCash & Debt
$1.13BReturn of Capital
$103.00MRevenue by Segment (annual)
$2.51BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.72B | $47.00M | $0.28 |
| 2024 | $2.51B | $-1.12B | $-6.50 |
| 2023 | $2.57B | $-100.20M | $-0.60 |
| 2022 | $2.57B | $243.10M | $1.46 |
| 2021 | $2.51B | $340.50M | $1.63 |
| 2020 | $1.93B | $33.30M | $0.27 |
| 2019 | $2.28B | $217.60M | $1.35 |
| 2018 | $2.84B | $230.70M | $1.80 |
| 2017 | $2.81B | $301.10M | $2.35 |
| 2016 | $2.79B | $272.00M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.41
- Implied price
- $7.40
- Return from $23.47
- -20.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.68 — -84.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -33.6% | -30.5% | -28.0% | -25.7% | -23.7% |
| 3.0% | -30.2% | -27.0% | -24.3% | -21.9% | -19.8% |
| 8.0% | -26.8% | -23.5% | -20.6% | -18.1% | -15.9% |
| 13.0% | -23.4% | -19.9% | -16.9% | -14.3% | -12.0% |
| 18.0% | -20.0% | -16.4% | -13.3% | -10.5% | -8.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
65+30.00%Social Signal Score
Mentions (19)
- Newszacks.com·10d ago·Positive
NVST vs. ABT: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newszacks.com·17d ago·Positive
Down 12% in 4 Weeks, Here's Why You Should You Buy the Dip in Envista (NVST) Envista (NVST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Envista Holdings Corporation (NVST) Analyst/Investor Day Transcript Envista Holdings Corporation (NVST) Analyst/Investor Day Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Envista Holdings Corporation (NVST) Presents at 2026 Global Healthcare Conference Transcript Envista Holdings Corporation (NVST) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·26d ago·Positive
NVST or ABT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsprnewswire.com·27d ago·Neutral
Envista Announces Participation in Baird 2026 Global Healthcare Conference BREA, Calif., Sept. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2026 Global Healthcare Conference.
View source ↗ - Newszacks.com·31d ago·Neutral
Envista (NVST) Up 0.8% Since Last Earnings Report: Can It Continue? Envista (NVST) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)investing·32d ago·Positive
Why is Envista stock rallying today?
View source ↗ - News (RSS)investing·32d ago·Positive
Envista Holdings stock rises on JPMorgan upgrade
View source ↗ - News (RSS)zerohedge·32d ago·Neutral
…its dividend and provided disappointing guidance. Ciena (CIEN) rises 1% after the maker of equipment used by telecom companies posted third quarter results. Envista (NVST) climbs 2% after JPMorgan upgraded the dental company to overweight, saying the firm is entering its investor day event later this month from a position of improved execution. Hewlett Packard Enterprise (HPE) falls 4% after reporting increasing sales that didn’t meet high expectations from investors. NetApp (NTAP) is down 8%, e…
View source ↗ - Newszacks.com·39d ago·Positive
Best Momentum Stocks to Buy for August 27th ONTO, VIRT and NVST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 27th, 2026.
View source ↗ - Newszacks.com·42d ago·Positive
Envista (NVST) Upgraded to Strong Buy: Here's What You Should Know Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·42d ago·Neutral
NVST or ABT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·42d ago·Neutral
Do Options Traders Know Something About Envista Stock We Don't? Investors need to pay close attention to NVST stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·49d ago·Positive
Here's Why Envista (NVST) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·52d ago·Positive
Can NVST Sustain Its 2026 Guidance Boost as Margins Keep Expanding? Envista raises 2026 guidance as stronger sales and expanding margins lift earnings, but China pricing, tariffs and a tougher Q4 loom.
View source ↗ - Newszacks.com·53d ago·Positive
Is NVST a Buy as Earnings Rebound but Valuation Remains Above Median? Envista's earnings rebound and raised 2026 guidance strengthen the case, but above-median valuation leaves less room for execution setbacks.
View source ↗ - Newszacks.com·56d ago·Positive
Investing in Envista (NVST)? Don't Miss Assessing Its International Revenue Trends Examine the evolution of Envista's (NVST) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Envista Q2 Earnings Call Highlights Envista NYSE: NVST reported second-quarter 2026 sales of $731 million, supported by 5% core revenue growth and contributions from foreign exchange and acquisitions that lifted total revenue growth to just over 7%.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.36 per share
Typical surprise +18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.41 vs $0.34beat
- Wed, May 6$0.36 vs $0.31beat
- Thu, Feb 5$0.38 vs $0.32beat
- Wed, Oct 29$0.32 vs $0.27beat
- Thu, Jul 31$0.26 vs $0.24beat
- Thu, May 1$0.24 vs $0.20beat
Estimates and results for NVST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NVST officers and directors.
- Bought
- —
- Sold
- $713k
0 trades
3 trades
- Reis Mischasold
- Reis Mischasold
- Reis Mischasold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Pete Sessionshouse · TX17 · disclosed Jun 6, 2024 (0d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.